Beam Therapeutics Inc. (BEAM) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Beam Therapeutics Inc. (BEAM) Bundle
Looking to determine the intrinsic value of Beam Therapeutics Inc.? Our BEAM DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | 51.8 | 60.9 | 377.7 | 614.6 | 1,000.0 | 1,627.0 | 2,647.4 | 4,307.5 |
Revenue Growth, % | 0 | 33.33 | 215916.67 | 17.51 | 520.01 | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 |
EBITDA | -71.7 | -128.0 | -392.5 | -324.3 | -156.5 | -542.6 | -882.8 | -1,436.4 | -2,337.2 | -3,802.9 |
EBITDA, % | -398061.11 | -533437.5 | -757.01 | -532.39 | -41.43 | -88.29 | -88.29 | -88.29 | -88.29 | -88.29 |
Depreciation | 5.4 | 9.5 | 16.4 | 22.6 | 20.0 | 336.9 | 548.1 | 891.9 | 1,451.1 | 2,361.1 |
Depreciation, % | 30038.89 | 39466.67 | 31.71 | 37.06 | 5.3 | 54.81 | 54.81 | 54.81 | 54.81 | 54.81 |
EBIT | -77.1 | -137.5 | -408.9 | -346.9 | -176.5 | -549.1 | -893.4 | -1,453.7 | -2,365.3 | -3,848.6 |
EBIT, % | -428100 | -572904.17 | -788.72 | -569.45 | -46.73 | -89.35 | -89.35 | -89.35 | -89.35 | -89.35 |
Total Cash | 91.8 | 299.7 | 965.6 | 1,078.1 | 1,189.9 | 614.6 | 1,000.0 | 1,627.0 | 2,647.4 | 4,307.5 |
Total Cash, percent | .5 | 1.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | 300.0 | .0 | .0 | 122.9 | 200.0 | 325.4 | 529.5 | 861.5 |
Account Receivables, % | 0 | 0 | 578.66 | 0 | 0 | 20 | 20 | 20 | 20 | 20 |
Inventories | .0 | .0 | -607.4 | .0 | .0 | -122.9 | -200.0 | -325.4 | -529.5 | -861.5 |
Inventories, % | 0 | 0 | -1171.51 | 0 | 0 | -20 | -20 | -20 | -20 | -20 |
Accounts Payable | 7.8 | 6.3 | 7.5 | 9.0 | 1.6 | 282.3 | 459.3 | 747.4 | 1,216.0 | 1,978.6 |
Accounts Payable, % | 43588.89 | 26308.33 | 14.42 | 14.82 | 0.42811 | 45.93 | 45.93 | 45.93 | 45.93 | 45.93 |
Capital Expenditure | -12.5 | -16.4 | -46.8 | -49.0 | -33.7 | -466.6 | -759.1 | -1,235.2 | -2,009.7 | -3,270.1 |
Capital Expenditure, % | -69544.44 | -68154.17 | -90.29 | -80.35 | -8.93 | -75.92 | -75.92 | -75.92 | -75.92 | -75.92 |
Tax Rate, % | -1.04 | -1.04 | -1.04 | -1.04 | -1.04 | -1.04 | -1.04 | -1.04 | -1.04 | -1.04 |
EBITAT | -77.2 | -181.2 | -376.6 | -351.5 | -178.3 | -540.4 | -879.3 | -1,430.7 | -2,327.9 | -3,787.8 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -76.4 | -189.6 | -98.5 | -683.6 | -199.5 | -389.4 | -913.3 | -1,486.0 | -2,417.9 | -3,934.1 |
WACC, % | 12.56 | 12.56 | 12.53 | 12.56 | 12.56 | 12.55 | 12.55 | 12.55 | 12.55 | 12.55 |
PV UFCF | ||||||||||
SUM PV UFCF | -5,794.2 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -4,013 | |||||||||
Terminal Value | -38,033 | |||||||||
Present Terminal Value | -21,058 | |||||||||
Enterprise Value | -26,852 | |||||||||
Net Debt | -263 | |||||||||
Equity Value | -26,589 | |||||||||
Diluted Shares Outstanding, MM | 77 | |||||||||
Equity Value Per Share | -344.63 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real BEAM financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Modify forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effects of your inputs on Beam Therapeutics’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step guidance.
Key Features
- 🔍 Real-Life BEAM Financials: Pre-filled historical and projected data for Beam Therapeutics Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Beam’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Beam’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Beam Therapeutics Inc. (BEAM) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Beam Therapeutics Inc. (BEAM)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Beam Therapeutics Inc. (BEAM) Calculator?
- Precision: Utilizes real Beam Therapeutics financial data for reliable results.
- Adaptability: Allows users to easily adjust and test various inputs.
- Efficiency: Eliminate the need to create a financial model from the ground up.
- Expert-Level: Crafted with the accuracy and functionality expected by industry professionals.
- Intuitive: Simple to navigate, making it accessible for users with varying levels of financial expertise.
Who Should Use Beam Therapeutics Inc. (BEAM)?
- Investors: Gain insights into innovative gene editing technologies for informed investment choices.
- Biomedical Researchers: Utilize cutting-edge research data to enhance your studies in genetic therapies.
- Healthcare Consultants: Adapt findings for client strategies in biotechnology and therapeutic development.
- Science Enthusiasts: Explore the advancements in genetic medicine and their implications for the future.
- Educators and Students: Leverage the company's research as a resource for learning in biotechnology courses.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Beam Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Beam Therapeutics Inc. (BEAM).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.